Oxford PharmaGenesis™: an independent future for continued success

Share Article

Oxford PharmaGenesis™, the independent HealthScience communications consultancy, celebrates new ownership today.

The company has been acquired from its founder, Dr Graham Shelton, by Oxford PharmaGenesis™ Holdings Ltd, a new group owned by a team of Oxford PharmaGenesis™ senior managers. Dr Shelton will remain actively involved in the business as a shareholder, as Chairman, and as a participant in key projects. The acquisition has been achieved without external funding, securing an independent future for this industry leader.

In recent years, Oxford PharmaGenesis™ has developed into a thriving global consultancy, with more than 120 employees across four offices in the UK, USA and Switzerland. A key factor in this success has been the owner-managed environment, offering the agility to respond rapidly to evolving client needs while maintaining consistency in company ethos. The transition in ownership ensures the company remains in the hands of those working day-to-day in a business where client needs come first.

Managing Director Dr Chris Winchester commented, “Graham has created a unique atmosphere here and we’re glad to be able to keep PharmaGenesis™ in the family.” Graham said, “I am delighted. The leadership team is committed to continuing the high-quality service philosophy that has served us so well. Importantly, we have some truly exciting plans for the next phase in the development of our business. We believe that this is good news for our clients, for our people and for our industry.”

For further information contact Chris Winchester at chris.winchester(at)pharmagenesis(dot)com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Winchester
Follow us on
Visit website